XML 37 R28.htm IDEA: XBRL DOCUMENT v3.23.2
Equity
 6 Months Ended
Jun. 30, 2023
Equity [Abstract]  
Stockholders' Equity Note Disclosure Stockholders' Equity
Shareholders Agreement

At the completion of the Smiths Medical acquisition on January 6, 2022, Smiths owned approximately 10.5% of the total outstanding shares of our common stock (see Note 3: Acquisitions). At closing, in connection with the issuance of the share consideration, we entered into a Shareholders Agreement (the “Shareholders Agreement”) with Smiths. The Shareholders Agreement imposes certain restrictions on Smiths including prohibiting certain transfers of the shares of our common stock issued (i) for 6 months following the closing of the acquisition and (ii) to certain of our competitors and certain other parties, as well as customary standstill limitations. The Shareholders Agreement also permits Smiths to designate one individual for election to our Board of Directors (the "Board") so long as Smiths beneficially owns at least 5.0% of the total outstanding shares of our common stock. On February 1, 2022, our Board appointed a new director designated by Smiths pursuant to the Shareholders Agreement who was elected to the Board at the 2022 Annual Meeting of Stockholders held in May 2022. This appointment expanded the size of our Board from eight to nine members. See our Current Report on Form 8-K filed on February 1, 2022 for additional information.

Treasury Stock

    In August 2019, our Board approved a share purchase plan to purchase up to $100.0 million of our common stock. This plan has no expiration date. During the three months ended June 30, 2023, we did not purchase any shares of our common stock under our share purchase plan. As of June 30, 2023, all of the $100.0 million available for purchase was remaining under the plan. We are currently limited on share purchases in accordance with the terms and conditions of our Credit Agreement (see Note 17: Long-Term Debt).
    For the six months ended June 30, 2023, we withheld 54,371 shares of our common stock from employee vested restricted stock units in consideration for $8.7 million in payments made on the employees' behalf for their minimum statutory income tax withholding obligations. For the six months ended June 30, 2022, we withheld 44,759 shares of our common stock from employee vested restricted stock units in consideration for $10.4 million in payments made on the employees' behalf for their minimum statutory income tax withholding obligations. Treasury stock is used to issue shares for stock option exercises and restricted stock grants.

Accumulated Other Comprehensive (Loss) Income ("AOCI")

    The components of AOCI, net of tax, were as follows (in thousands):
Foreign Currency Translation AdjustmentsUnrealized (Losses) Gains on Cash Flow HedgesOther AdjustmentsTotal
Balance as of January 1, 2023$(122,973)$40,779 $1,216 $(80,978)
Other comprehensive income (loss) before
reclassifications		24,983 (113)(31)24,839 
Amounts reclassified from AOCI— (5,464)— (5,464)
Other comprehensive income (loss)24,983 (5,577)(31)19,375 
Balance as of March 31, 2023$(97,990)$35,202 $1,185 $(61,603)
Other comprehensive (loss) income before reclassifications7,569 13,175 (34)20,710 
Amounts reclassified from AOCI— (7,901)— (7,901)
Other comprehensive income (loss)7,569 5,274 (34)12,809 
Balance as of June 30, 2023$(90,421)$40,476 $1,151 $(48,794)

Foreign Currency Translation AdjustmentsUnrealized (Losses) Gains on Cash Flow HedgesOther AdjustmentsTotal
Balance as of January 1, 2022$(19,045)$(237)$13 $(19,269)
Other comprehensive (loss) income before
reclassifications		(4,946)25,782 15 20,851 
Amounts reclassified from AOCI— (2,210)— (2,210)
Other comprehensive (loss) income(4,946)23,572 15 18,641 
Balance as of March 31, 2022$(23,991)$23,335 $28 $(628)
Other comprehensive (loss) income before reclassifications(99,805)10,245 14 (89,546)
Amounts reclassified from AOCI— (2,101)— (2,101)
Other comprehensive (loss) income(99,805)8,144 14 (91,647)
Balance as of June 30, 2022$(123,796)$31,479 $42 $(92,275)